Analysts’ Top Healthcare Picks: EIGR, SCMP

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eiger Biopharmaceuticals (NASDAQ: EIGR), Sucampo Pharmaceuticals (NASDAQ: SCMP) and Paratek Pharmaceuticals (NASDAQ: PRTK) with bullish sentiments.

Eiger Biopharmaceuticals (NASDAQ: EIGR)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Eiger Biopharmaceuticals (NASDAQ: EIGR), with a price target of $34. The company’s shares opened today at $6.95, close to its 52-week low of $6.10.

Moussatos wrote:

“The Wedbush View: With four drug candidates being tested in four indications and enough cash runway to cover data readouts over the next 12 months, we believe EIGR is trading at an attractive value and recommend shares to investors.”

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 11.5% and a 45.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Catabasis Pharmaceuticals, and miRagen Therapeutics Inc.

Currently, the analyst consensus on Eiger Biopharmaceuticals is Strong Buy and the average price target is $32.33, representing a 365.2% upside.

In a report issued on June 7, Oppenheimer also reiterated a Buy rating on the stock with a $34 price target.
Sucampo Pharmaceuticals (NASDAQ: SCMP)

In a report released today, Michael Higgins from Roth Capital reiterated a Buy rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), with a price target of $29.50. The company’s shares opened today at $10.35, close to its 52-week low of $9.30.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -14.6% and a 29.2% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Juniper Pharmaceuticals, and Zynerba Pharmaceuticals.

Sucampo Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $18.63.

Paratek Pharmaceuticals (NASDAQ: PRTK)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK) today and set a price target of $50. The company’s shares opened today at $23.55, close to its 52-week high of $25.05.

Chen said:

“The longer you stay in the hospital, the longer you stay. The once-daily, oral- only dosing regimen is a strategically important part of Paratek’s “stay home” strategy for Omadacycline. The broad spectrum activity of Omadacycline and its well-tolerated, once-daily oral dosage, offers significant potential to effectively treat infection while allowing patients to stay home.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -14.4% and a 33.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.

Currently, the analyst consensus on Paratek Pharmaceuticals is Strong Buy and the average price target is $34.80, representing a 47.8% upside.

In a report issued on June 15, Leerink Swann also reiterated a Buy rating on the stock with a $37 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.